This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-24. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Immediately after the attacks, the Federal Bureau of Investigation (FBI) started PENTTBOM, the largest criminal inquiry in U.S. history. At its height, more than half of the FBI's agents worked on the investigation and followed a half-million leads. The FBI concluded that there was "clear and irrefutable" evidence linking al-Qaeda and bin Laden to the attacks.
An indicative cost structure for a fine chemical company is shown in Table 10. Nowadays, a full 7-day/week operation, consisting of four or five shift teams, each working 8h per day, has become the standard. In terms of production costs, this is the most advantageous scheme. Higher salaries for night work are more than offset by better fixed cost absorption. As part of the budgeting process, standard costs for a production campaign of a particular fine chemical are determined on the basis of past experience. The actual results of the campaign are then compared with the standard. The capability of a fine chemical company to make dependable manufacturing cost forecasts is a distinct competitive advantage.
== Effectiveness == A landmark randomized placebo control trial on NASHA Dx was published in 2011 in the Lancet. 136 were given real injections and 70 patients were given shame (fake) injections. 80% of the patients had no improvement 1 month after the procedure, and were given a second injection. After 6 months, 52% of patients who received real injections had improved symptoms. However, the patients who received fake injections reported over 30% improvement in symptoms, suggesting that patient psychology (i.e. the placebo effect) may be in part responsible for any positive results. 6% of patients who received real injections were fully continent after 6 months. After publication of this study, the material was approved by the FDA in the USA in 2012. The material was aggressively marketed, and became popular for a time because of its potential as an in office treatment with low risks compared to other surgical options. However uncertainty about indications, cost, and long term durability stopped widespread adoption. A Cochrane systematic review of the efficacy of this type of treatment for FI was updated in 2013. The review included 5 randomized trials, which in total was 382 patients. 4 of the trials were assessed as uncertain or high risk of bias. Another commentator drew attention to the fact that all existing research on these procedures was driven by the companies who also marketed the treatments, and therefore the studies are indeed at high risk of bias.
=== Mechanism of action === Clonazepam enhances the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system to give its anticonvulsant, skeletal muscle relaxant, and anxiolytic effects. It acts by binding to the benzodiazepine site of the GABA receptors, which enhances the electric effect of GABA binding on neurons, resulting in an increased influx of chloride ions into the neurons. This further results in an inhibition of synaptic transmission across the central nervous system. Benzodiazepines do not have any effect on the levels of GABA in the brain. Clonazepam has no effect on GABA levels and has no effect on gamma-aminobutyric acid transaminase. Clonazepam does, however, affect glutamate decarboxylase activity. It differs from other anticonvulsant drugs it was compared to in a study. Clonazepam's primary mechanism of action is the modulation of GABA function in the brain, by the benzodiazepine receptor, located on GABAA receptors, which, in turn, leads to enhanced GABAergic inhibition of neuronal firing. Benzodiazepines do not replace GABA, but instead enhance the effect of GABA at the GABAA receptor by increasing the opening frequency of chloride ion channels, which leads to an increase in GABA's inhibitory effects and resultant central nervous system depression. In addition, clonazepam decreases the utilization of 5-HT (serotonin) by neurons and has been shown to bind tightly to central-type benzodiazepine receptors.
Sources: en.wikipedia.org
The ascent led through forests of chestnut, laurels, and heaths, and onto higher, barren volcanic plains such as Llano del Retama, where vegetation diminished and only shrubs and wildlife remained. At Estancia de los Ingleses, a traditional rest point at about 8,000 feet (2,400 m), the group endured a cold, windy night before continuing the climb at 3 a.m. on 22 June 1799. They crossed the Malpays, an area of broken lava and little vegetation, and reached the summit at 8 a.m. At the peak, the party observed the structure of the volcano, measured ground temperatures, and collected air samples. The elliptical crater showed no recent eruptions inside, but the volcano remained active, with recent lava flows and geothermal activity. The summit provided panoramic views of the surrounding islands and the diverse ecological zones descending from the peak, which Humboldt recorded in a sketch. He noted five distinct vegetation zones, from grasses at the summit to cultivated tropical and temperate plants near the coast. The descent took the party back through the varying ecological regions. Humboldt made broader geological observations, considering questions about the structure and origins of volcanoes and the laws governing geological phenomena. The round trip from La Orotava to the summit and back lasted twenty-one hours. The Pizarro’s departure was delayed until 24 or 25 June 1799 due to the presence of an English squadron, allowing Humboldt and Bonpland additional time to explore the island’s surroundings.
=== Cancer therapy === Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs; they can also be activated by some therapies to promote antitumor immunity. Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies, radiotherapies and immunotherapies. Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients. However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies. Similarly, studies identified macrophages genetically engineered to express chimeric antigen receptors as promising therapeutic approach to lowering tumor burden.
=== Traditional accelerationism === Traditional accelerationism, as developed by the British philosopher Nick Land, sees the acceleration of technological change as a way to bring about a fundamental transformation of current culture, society, and the political economy. This is done through capitalism, which Land views as "an autonomous force that’s reconfiguring society" that can overcome its limits if intensified. Land's work has also been characterized as concerning "the supposedly inevitable 'disintegration of the human species' when artificial intelligence improves sufficiently." While both concern ideas like a technocapital singularity and AGI progress, effective accelerationism focuses on using AGI for the greatest ethical good for conscious life and civilization (whether human or machine), as well as expanding civilization and maximizing energy usage in order to align with the "will of the universe". Land focuses on capitalist self-optimization as the driver of modernity, progress, and the eroding of existing social orders. Land has expressed support for effective accelerationism, while Thomas Murphy referred to the movement as "Nick Land diluted for LinkedIn".
=== Excretion === A few minutes after ingestion, strychnine is excreted unchanged in the urine, and accounts for about 5 to 15% of a sublethal dose given over 6 hours. Approximately 10 to 20% of the dose will be excreted unchanged in the urine in the first 24 hours. The percentage excreted decreases with the increasing dose. Of the amount excreted by the kidneys, about 70% is excreted in the first 6 hours, and almost 90% in the first 24 hours. Excretion is virtually complete in 48 to 72 hours.
== Chondrocyte Primary Culture == Chondrocytes can be prepared by sequential enzymatic digestion of cartilage with Pronase and Collagenase and cultured in DMEM-F12 cell culture media. Transplantation of dedifferentiated chondrocytes often leads to the formation of fibrous tissue formation. Redifferentiation of dedifferentiated chondrocytes in the 3-D system (spheroid culture) restore morphological and functional properties.
Sources: en.wikipedia.org
He says he will be able to find "common ground" with the US president-elect. MP for Runcorn and Helsby, Mike Amesbury, is to be charged with common assault, following a police investigation into video footage that appeared to show him punching a man to the ground in the street. Amesbury was suspended from the Labour Party after the video emerged. 8 November – Jonathan Powell, a former Chief of Staff to Tony Blair, is appointed as the UK's national security adviser, replacing Sir Tim Barrow. 9 November – Former Health Secretary Alan Milburn, who served in the Blair government, is appointed as a non-executive director on the board of the Department of Health. 10 November – Treasury minister Darren Jones tells BBC One's Sunday with Laura Kuenssberg the UK government's commitment to Ukraine is "resolute" amid concerns Donald Trump could push the country into giving up territory to Russia once he becomes president. First Minister of Northern Ireland Michelle O'Neill becomes the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony, held in Belfast. 11 November – The Terminally Ill Adults (End of Life) Bill, which would allow terminally ill people in England and Wales with less than six months to live to seek assistance in ending their lives, with the consent of two doctors and a High Court judge, is published. At the invitation of French president Emmanuel Macron, Starmer travels to France to mark Armistice Day at the Tomb of the Unknown Soldier, then holds talks with Macron to affirm the UK and France's commitment to supporting Ukraine.
2,5-Diketopiperazine is an organic compound with the formula (NHCH2C(O))2. The compound features a six-membered ring containing two amide groups at opposite positions in the ring. It was first compound containing a peptide bond to be characterized by X-ray crystallography in 1938. It is the parent of a large class of 2,5-Diketopiperazines (2,5-DKPs) with the formula (NHCH2(R)C(O))2 (R = H, CH3, etc.). They are ubiquitous peptides in nature. They are often found in fermentation broths and yeast cultures as well as embedded in larger more complex architectures in a variety of natural products as well as several drugs. In addition, they are often produced as degradation products of polypeptides, especially in foods and beverages. They have also been found in extraterrestrial objects such as comets and asteroids.
Plutonium recovered from LWR spent fuel, while not weapons grade, can be used to produce nuclear weapons at all levels of sophistication, though in simple designs it may produce only a fizzle yield. Weapons made with reactor-grade plutonium would require special cooling to keep them in storage and ready for use. A 1962 test at the U.S. Nevada National Security Site (then known as the Nevada Proving Grounds) used non-weapons-grade plutonium produced in a Magnox reactor in the United Kingdom. The plutonium used was provided to the United States under the 1958 US–UK Mutual Defence Agreement. Its isotopic composition has not been disclosed, other than the description reactor grade, and it has not been disclosed which definition was used in describing the material this way. The plutonium was apparently sourced from the Magnox reactors at Calder Hall or Chapelcross. The content of Pu-239 in material used for the 1962 test was not disclosed, but has been inferred to have been at least 85%, much higher than typical spent fuel from currently operating reactors. Occasionally, low-burnup spent fuel has been produced by a commercial LWR when an incident such as a fuel cladding failure has required early refuelling. If the period of irradiation has been sufficiently short, this spent fuel could be reprocessed to produce weapons grade plutonium.
=== Mechanism of action === Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of renal glucose reabsorption (the remaining 10% is done by SGLT1 inhibition). Blocking this transporter causes up to 119 grams of blood glucose per day to be eliminated through the urine, corresponding to 476 kilocalories. Additional water is eliminated by osmotic diuresis, resulting in a lowering of blood pressure. This mechanism is associated with a low risk of hypoglycaemia (too low blood glucose) compared to other types of anti-diabetic drugs such as sulfonylurea derivatives and insulin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.